Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held M...
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conf...
2023-05-11 12:38:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it’s not particularly likely to happen. Indeed, such an endeavor requires a...
2023-05-11 06:58:43 ET Synlogic press release ( NASDAQ: SYBX ): Q1 GAAP EPS of -$0.23 in-line. Revenue of $0.17M (-29.2% Y/Y) beats by $0.03M . For further details see: Synlogic GAAP EPS of -$0.23 in-line, revenue of $0.17M beats by $0.03M
- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from the EMA for SYNB1934 as a potential treatment for PKU - ...
2023-05-09 07:34:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! Moving stocks today are earnings reports, dividends, p...
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of...
2023-03-31 10:10:00 ET Vancouver, Kelowna, Delta, BC - March 31, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Energy, Biotech and Cannabis. Today's stocks have been added to o...
2023-03-29 06:44:45 ET Synlogic press release ( NASDAQ: SYBX ): Q4 GAAP EPS of -$0.24 beats by $0.02 . Revenue of $0.11M (-81.4% Y/Y) misses by $0.12M . As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 ...
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster pr...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, t...
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company...